While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...
Walgreens jumps as Sycamore agrees to $11.45 a share purchase Sycamore Partners agreed to acquire Walgreens Boots (WBA) in a ...
Hims & Hers Health will shut down Apostrophe, its personalized acne treatments dermatology business, the company said on Friday. Apostrophe is being shut down to “simplify its (company’s) dermatology ...
Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on ...
While the Super Bowl may not always be the ideal spot for pharma, cultural events like the Oscars can offer a more ...
The makers of two popular weight-loss drugs—Wegovy and Zepbound—are cutting prices to make the medications more affordable for people without insurance. Novo Nordisk, the Danish company behind Wegovy, ...
The makers of two popular weight-loss drugs — Wegovy and Zepbound — are cutting prices to make the medications more af ...
From STAT’s Elaine Chen: A federal judge this week ruled against a compounding trade group that wanted to continue making ...
Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...
Zacks Investment Research on MSN2d
Pharma Stock Roundup: BAYRY's Q4 Results, ABBV's Obesity Deal & MoreBayer BAYRY announced its fourth-quarter and full-year 2024 results. AbbVie ABBV announced a licensing deal with Danish firm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback